Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders

Digestive Diseases and Sciences

Volumn 59, Issue 7, 2014, Pages 1436-1441

  Baraniskin, Alexander ^a,b   Nöpel Dünnebacke, Stefanie ^a,b   Schumacher, Brigitte ^c   Gerges, Christian ^c   Bracht, Thilo ^a   Sitek, Barbara ^a   Meyer, Helmut E ^a,d   Gerken, Guido ^e   Dechene, Alexander ^e   Schlaak, Jörg F ^e,f   Schroers, Roland ^b   Pox, Christian ^b   Schmiegel, Wolff ^b   Hahn, Stephan A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Children s Hospital   (Germany)

^d LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f Evangelisches Klinikum Niederrhein   (Germany)

Author keywords

Bile; Cholangiocarcinoma; Diagnosis; Primary sclerosing cholangitis; RNU2 1; U2 snRNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; SMALL NUCLEAR RNA; U2 SMALL NUCLEAR RNA FRAGMENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE LEVEL; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA, SMALL NUCLEAR; SENSITIVITY AND SPECIFICITY;

EID: 84903537066     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3034-5     Document Type: Article

References (26)

1. Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62:122-130.
2. Demols A, Marechal R, Devière J, et al. The multidisciplinary management of gastrointestinal cancer. Biliary tract cancers: from pathogenesis to endoscopic treatment. Best Pract Res Clin Gastroenterol. 2007;21:1015e29.
3. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:204-207. (Pubitemid 30041560)
4. Chapman MH, Sandanayake NS, Andreola F, et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol. 2011;1:6-12.
5. Weismüller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitiseaetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:S38e57.
6. de Bellis M, Fogel EL, Sherman S, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc. 2008;58:176e82.
7. Clayton RA, Clarke DL, Currie EJ, et al. Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy. Surgeon. 2003;1:32-38. (Pubitemid 36575688)
8. Gerhards MF, Vos P, van Gulik TM, et al. Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg. 2001;88:48-51. (Pubitemid 32066056)
9. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002; 36:321e7.
10. Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132:E48-E57.
11. Mazières J, Catherinne C, Delfour O, et al. Alternative processing of the u2 small nuclear RNA produces a 19-22nt fragment with relevance for the detection of non-small cell lung cancer in human serum. PLoS One. 2013;8:e60134.
12. Will CL, Lührmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol. 2001;13:290-301. (Pubitemid 32429493)
13. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105:10513-10518.
14. Langenberger D, Bartschat S, Hertel J, et al. MicroRNA or not microRNA? Lecture notes in computer science. Springer: Heidelberg; 2011:1-9.
15. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulatingmicroRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108:5003-5008.
16. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucl Acids Res. 2010;38:7248-7259.
17. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucl Acids Res. 2011;39: 7223-7233.
18. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol. 2011;13:423-433.
19. Eissa NT. The exosome in lung diseases: message in a bottle. J Allergy Clin Immunol. 2013;131:904-905.
20. Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52:297-303.
21. Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating b-catenin. Gastroenterology. 2012;143: 246-256.
22. Zhong XY, Yu JH, Zhang WG, et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene. 2012;493:44-51.
23. Chen Y, Luo J, Tian R, et al. miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci. 2011;56:1693-1701.
24. Selaru FM, Olaru AV, Kan T, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595-1601.
25. McNally ME, Collins A, Wojcik SE, et al. Concomitant dysregulation of microRNAs miR-151-3p, miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford). 2013;15:260-264.
26. Papaconstantinou I, Karakatsanis A, Gazouli M, et al. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol. 2012;24: 223-228.